Boston Scientific (BSX) Common Equity (2009 - 2026)

Boston Scientific (BSX) has 18 years of Common Equity data on file, last reported at $25.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 15.23% year-over-year to $25.9 billion; the trailing twelve-month figure through Mar 2026 stood at $25.9 billion (up 15.23% YoY), and the FY2025 full-year result was $24.2 billion, up 11.31% from the prior year.
• Common Equity rose to $25.9 billion in Q1 2026, from $24.2 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $25.9 billion in Q1 2026 to a low of -$2.3 billion in Q1 2022.
• A 5-year average of $12.5 billion and a median of $18.9 billion in 2023 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 16904.55% in 2025, while the deepest fall reached 4407.69% in 2025.
• Tracing BSX's Common Equity over 5 years: stood at $269.0 million in 2022, then soared by 7160.22% to $19.5 billion in 2023, then climbed by 11.47% to $21.8 billion in 2024, then advanced by 11.31% to $24.2 billion in 2025, then gained by 6.73% to $25.9 billion in 2026.
• Business Quant data shows BSX's Common Equity at $25.9 billion in Q1 2026, $24.2 billion in Q4 2025, and $23.6 billion in Q3 2025.